These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 4216116)

  • 1. Molecular aspects of the clottable proteins of human plasma during fibrinogenolysis.
    Ly B; Kierulf P; Arnesen H
    Thromb Res; 1974 Sep; 5(3):301-14. PubMed ID: 4216116
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on soluble fibrin in plasma. V. Isolation and characterization of the clottable proteins obtained from patient plasmas upon gelation with ethanol.
    Kierulf P
    Thromb Res; 1974 Jan; 4(1):183-7. PubMed ID: 4829666
    [No Abstract]   [Full Text] [Related]  

  • 3. Interaction between red cell membranes and fibrinogen.
    Murray M; Rearick DE
    Thromb Res; 1974 Feb; 4(2):261-9. PubMed ID: 4831004
    [No Abstract]   [Full Text] [Related]  

  • 4. Fibrinogen and its derivatives, hereditary and acquired abnormalities.
    Marder VJ; Buszynski AZ
    Schweiz Med Wochenschr; 1974 Sep; 104(39):1338-42. PubMed ID: 4421373
    [No Abstract]   [Full Text] [Related]  

  • 5. Fibrinogen of relatively high solubility, III. Residual clottable material in plasma deprived of the majority of fibrinogen.
    Jilg W; Hörmann H
    Hoppe Seylers Z Physiol Chem; 1974 Oct; 355(10):1316-24. PubMed ID: 4461634
    [No Abstract]   [Full Text] [Related]  

  • 6. Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin.
    Weitz JI; Leslie B
    J Clin Invest; 1990 Jul; 86(1):203-12. PubMed ID: 2365816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tranexamic acid on fibrinolysis, fibrinogenolysis and amidolysis.
    Takada A; Makino Y; Takada Y
    Thromb Res; 1986 Apr; 42(1):39-47. PubMed ID: 3705023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y; Scully MF; Ellis V; Kakkar VV
    Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
    Thorsen S; Müllertz S; Suenson E; Kok P
    Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human fibrinogen heterogeneity. A study of limited fibrinogen degradation.
    Regañón E; Vila V; Aznar J; Laiz B
    Clin Chim Acta; 1989 Sep; 184(1):7-17. PubMed ID: 2532081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on soluble fibrin in plasma. I a. N-terminal analysis of a modified fraction I (Cohn) from plasma containing fibrinolytic inhibitors, and incubated with plasminogen-free human thrombin.
    Kierulf P
    Scand J Clin Lab Invest; 1972 May; 29(3):253-7. PubMed ID: 5037622
    [No Abstract]   [Full Text] [Related]  

  • 12. Proceedings: Fibrinogen degradation of normal and fibrinolytic plasma.
    Scully MF; Kakkar VV
    Thromb Diath Haemorrh; 1975 Nov; 34(2):584. PubMed ID: 53894
    [No Abstract]   [Full Text] [Related]  

  • 13. The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light (B) chain-streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light (B) chain.
    Summaria L; Boreisha IG; Arzadon L; Robbins KC
    Thromb Res; 1977 Sep; 11(3):377-89. PubMed ID: 144332
    [No Abstract]   [Full Text] [Related]  

  • 14. Fibrinolysis of soluble and polymerized des-AA/des-AABB fibrin compared to fibrinogenolysis in buffer and in fibrinogen-boosted serum. Evidence that plasminogen activators are responsible for preferential degradation of polymerized fibrin.
    Brosstad F
    Thromb Res; 1979; 15(3-4):497-504. PubMed ID: 158847
    [No Abstract]   [Full Text] [Related]  

  • 15. Activation of Glu-plasminogen by urokinase in the presence of fibrinogen, fibrin, and SK-potentiator.
    Takada A; Takada Y
    Thromb Res; 1981 May; 22(4):497-501. PubMed ID: 6457416
    [No Abstract]   [Full Text] [Related]  

  • 16. Cleavage of the A alpha-chain of fibrinogen and the alpha-polymer of fibrin by the venom of spitting cobra (Naja nigricollis).
    Evans HJ
    Biochim Biophys Acta; 1981 Aug; 660(2):219-26. PubMed ID: 6793073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fibrin on the enhanced activation of plasminogen by urokinase and tissue plasminogen activator: role of cross-link.
    Takada A; Watahiki Y; Takada Y
    Thromb Res; 1986 Mar; 41(5):605-13. PubMed ID: 3083529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK).
    Lipinski B; Gurewich V; Hyde E
    Thromb Diath Haemorrh; 1975 Sep; 34(1):351. PubMed ID: 1188799
    [No Abstract]   [Full Text] [Related]  

  • 20. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
    Müllertz S
    Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.